未平仓空仓比减少最大的10只股票 | 股票名称 | 上一次空仓比 | 最新空仓比 | | 减少值↓ | | --- | --- | --- | --- | --- | | 协鑫科技(03800) | 11.76% | 8.59% | -3.16% | | | 东方电气(01072) | 6.78% | 4.75% | -2.03% | | | 锦欣生殖(01951) | 10.61% | 9.85% | -0.76% | | | 长飞光纤光缆(06869) | 7.03% | 6.28% | -0.75% | | | 上海电气(02727) | 2.25% | 1.52% | -0.72% | | | 金山云(03896) | 4.26% | 3.54% | -0.72% | | --- | --- | --- | --- | | 比亚迪电子(00285) | 5.75% | 5.07% | -0.68% | | 耀才证券金融(01428) | 5.63% | 4.98% | -0.65% | | 中国中免(01880) | 6.83% | 6.18% | -0.65% | | 中远海运国际(00517) | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

消息面上，微创医疗宣布重组心律管理业务，附属微创心通拟合并CRM Cayman。有市场人士指出，此 次合并意在化解心律业务"达标上市"对赌压力。摩通大根表示，交易顺利完成，有助消除持续困扰公司 的重大不明朗因素。此外，公司此前引入国企背景的上海实业作为战略股东。国泰海通证券表示，上实 资本依托其国资背景和产业资源，有望助力集团核心业务拓展及潜在战略并购，追求更卓越的公司治理 水平，为集团持续创新、高质量发展及规模能级提升提供支持。 微创医疗(00853)尾盘再涨5%，截至发稿，涨5.1%，报16.08港元，成交额2.67亿港元。 ...

智通财经APP获悉，微创医疗(00853)尾盘再涨5%，截至发稿，涨5.1%，报16.08港元，成交额2.67亿港 元。 消息面上，微创医疗宣布重组心律管理业务，附属微创心通拟合并CRM Cayman。有市场人士指出，此 次合并意在化解心律业务"达标上市"对赌压力。摩通大根表示，交易顺利完成，有助消除持续困扰公司 的重大不明朗因素。此外，公司此前引入国企背景的上海实业作为战略股东。国泰海通证券表示，上实 资本依托其国资背景和产业资源，有望助力集团核心业务拓展及潜在战略并购，追求更卓越的公司治理 水平，为集团持续创新、高质量发展及规模能级提升提供支持。 ...

美银证券发布研报称，公司此前引入国企背景的上海实业作为战略股东，将支持财务与业务发展。该行 预期，通过成本控制与处置非核心资产，公司有望于2026年上半年实现盈利。另外，海外业务快速增 长，亦可分散国内市场风险，并提供长远增长能见度。 消息面上，微创医疗近日宣布重组心律管理业务。附属微创心通拟合并CRM Cayman。完成合并后， CRM Cayman将成为微创心通的全资附属。此前有市场人士指出，此次合并意在化解心律业务"达标上 市"对赌压力。摩通大根则表示，交易顺利完成，有助消除持续困扰公司的重大不明朗因素。 智通财经APP获悉，微创医疗(00853)再涨近5%，截至发稿，涨4.53%，报15港元，成交额8686.59万港 元。 ...

美银证券发布研报称，公司此前引入国企背景的上海实业作为战略股东，将支持财务与业务发展。该行 预期，通过成本控制与处置非核心资产，公司有望于2026年上半年实现盈利。另外，海外业务快速增 长，亦可分散国内市场风险，并提供长远增长能见度。 微创医疗(00853)再涨近5%，截至发稿，涨4.53%，报15港元，成交额8686.59万港元。 消息面上，微创医疗近日宣布重组心律管理业务。附属微创心通拟合并CRM Cayman。完成合并后， CRM Cayman将成为微创心通的全资附属。此前有市场人士指出，此次合并意在化解心律业务"达标上 市"对赌压力。摩通大根则表示，交易顺利完成，有助消除持续困扰公司的重大不明朗因素。 ...

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

消息面上，微创医疗近日宣布重组心律管理业务。附属微创心通拟合并CRM Cayman。完成合并后， CRM Cayman将成为微创心通的全资附属，其主要从事心律管理业务，专注于心律失常管理解决方案， 其交易前股权价值为6.8亿美元。目前，微创医疗持有心通医疗46.12%；并持有CRM Cayman 50.13%权 益。 摩通大根认为，公司已就将其心律管理业务(CRM)与心通医疗合并达成最终协议。该行认为交易顺利完 成，有助消除持续困扰公司的重大不明朗因素。美银证券指出，公司引入国企背景的上海实业作为战略 股东，将支持财务与业务发展。该行预期，通过成本控制与处置非核心资产，公司有望于2026年上半年 实现盈利。另外，海外业务快速增长，亦可分散国内市场风险，并提供长远增长能见度。 智通财经APP获悉，微创医疗(00853)涨近5%，截至发稿，涨4.74%，报14.36港元，成交额7918.4万港 元。 ...

Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

Group 1 - The company announced the resignation of Mr. Haiteng Bai as non-executive director, honorary chairman, and member of the strategic committee effective September 30, 2025, to dedicate more time to other business activities [1] - Mr. Norihiro Adachi also resigned as non-executive director and member of the audit committee for similar reasons [1] - Dr. Gu Feng has been appointed as a non-executive director and member of the nomination and remuneration committees [1] Group 2 - Dr. Men Qingbing has been appointed as a non-executive director, member of the audit committee, and chairman of the strategic committee [1] - Dr. Chang Zhaohua is no longer a member of the remuneration committee and chairman of the strategic committee [1] - Mr. Zhou Jia Hong has been appointed as a member of the nomination committee [1]